Do analysts recommend ELAB or ACXP?

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 2,008.84%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than PMGC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ELAB or ACXP more profitable?

PMGC's return on equity of -117.82% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMGC N/A -117.82% -70.79% Acurx Pharmaceuticals N/A -153.92% -101.69%

Do analysts recommend ELAB or CNSP?

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than PMGC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ELAB or CNSP more profitable?

PMGC's return on equity of -117.82% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMGC N/A -117.82% -70.79% CNS Pharmaceuticals N/A -238.68% -166.30%

Do analysts recommend BMRA or ELAB?

Biomerica currently has a consensus target price of $9.00, suggesting a potential upside of 414.29%. Given Biomerica's higher probable upside, equities analysts clearly believe Biomerica is more favorable than PMGC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, BMRA or ELAB?

Biomerica has higher revenue and earnings than PMGC. Biomerica is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomerica $5.31M 1.02 -$4.97M -$0.89 N/A PMGC $1.27M 1.14 -$7.75M -$168.62 N/A

Is BMRA or ELAB more profitable?

PMGC has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Biomerica's return on equity of -98.14% beat PMGC's return on equity. Company Net Margins Return on Equity Return on Assets Biomerica -96.49% -98.14% -70.42% PMGC N/A -117.82% -70.79%

Does the media prefer BMRA or ELAB?

In the previous week, PMGC had 1 more articles in the media than Biomerica. MarketBeat recorded 2 mentions for PMGC and 1 mentions for Biomerica. Biomerica's average media sentiment score of 0.67 beat PMGC's score of 0.00 indicating that Biomerica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomerica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PMGC 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BDRX or ELAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, BDRX or ELAB?

PMGC has higher revenue and earnings than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A PMGC $1.27M 1.14 -$7.75M -$168.62 N/A

Is BDRX or ELAB more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat PMGC's return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A PMGC N/A -117.82% -70.79%

Do analysts prefer APVO or ELAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is APVO or ELAB more profitable?

PMGC's return on equity of -117.82% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% PMGC N/A -117.82% -70.79%

PMGC (ELAB) Competitors

$1.25 -0.07 (-5.30%)

Closing price 04:00 PM Eastern

Extended Trading

$1.25 0.00 (-0.32%)

As of 05:24 PM Eastern

Compare

ELAB vs. ACXP, CNSP, BMRA, BDRX, and APVO

Should you buy PMGC stock or one of its competitors? MarketBeat compares PMGC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PMGC include Acurx Pharmaceuticals (ACXP), CNS Pharmaceuticals (CNSP), Biomerica (BMRA), Biodexa Pharmaceuticals (BDRX), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical products" industry.

How does PMGC compare to Acurx Pharmaceuticals?

PMGC (NASDAQ:ELAB) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

PMGC has higher revenue and earnings than Acurx Pharmaceuticals. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMGC	$1.27M	1.14	-$7.75M	-$168.62	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

PMGC's return on equity of -117.82% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMGC	N/A	-117.82%	-70.79%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

22.2% of PMGC shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 0.0% of PMGC shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PMGC has a beta of -0.27, indicating that its stock price is 127% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market.

In the previous week, PMGC had 2 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 2 mentions for PMGC and 0 mentions for Acurx Pharmaceuticals. PMGC's average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PMGC	Neutral
Acurx Pharmaceuticals	Neutral

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 2,008.84%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than PMGC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

PMGC beats Acurx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does PMGC compare to CNS Pharmaceuticals?

PMGC (NASDAQ:ELAB) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than PMGC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PMGC's return on equity of -117.82% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMGC	N/A	-117.82%	-70.79%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

PMGC has a beta of -0.27, indicating that its share price is 127% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market.

In the previous week, PMGC had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 2 mentions for PMGC and 0 mentions for CNS Pharmaceuticals. PMGC's average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PMGC	Neutral
CNS Pharmaceuticals	Neutral

22.2% of PMGC shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 0.0% of PMGC shares are held by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PMGC has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMGC	$1.27M	1.14	-$7.75M	-$168.62	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

Summary

PMGC beats CNS Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does PMGC compare to Biomerica?

Biomerica (NASDAQ:BMRA) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

PMGC has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Biomerica's return on equity of -98.14% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
PMGC	N/A	-117.82%	-70.79%

In the previous week, PMGC had 1 more articles in the media than Biomerica. MarketBeat recorded 2 mentions for PMGC and 1 mentions for Biomerica. Biomerica's average media sentiment score of 0.67 beat PMGC's score of 0.00 indicating that Biomerica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomerica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PMGC	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biomerica has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, PMGC has a beta of -0.27, meaning that its stock price is 127% less volatile than the broader market.

Biomerica has higher revenue and earnings than PMGC. Biomerica is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$5.31M	1.02	-$4.97M	-$0.89	N/A
PMGC	$1.27M	1.14	-$7.75M	-$168.62	N/A

Biomerica currently has a consensus target price of $9.00, suggesting a potential upside of 414.29%. Given Biomerica's higher probable upside, equities analysts clearly believe Biomerica is more favorable than PMGC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 22.2% of PMGC shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 0.0% of PMGC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Biomerica beats PMGC on 10 of the 14 factors compared between the two stocks.

How does PMGC compare to Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 22.2% of PMGC shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of PMGC shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PMGC has higher revenue and earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
PMGC	$1.27M	1.14	-$7.75M	-$168.62	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals' return on equity of 0.00% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
PMGC	N/A	-117.82%	-70.79%

In the previous week, PMGC had 2 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 2 mentions for PMGC and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled PMGC'saverage media sentiment score.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
PMGC	Neutral

Biodexa Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, PMGC has a beta of -0.27, indicating that its stock price is 127% less volatile than the broader market.

Summary

Biodexa Pharmaceuticals and PMGC tied by winning 4 of the 8 factors compared between the two stocks.

How does PMGC compare to Aptevo Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Aptevo Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, PMGC has a beta of -0.27, suggesting that its stock price is 127% less volatile than the broader market.

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 22.2% of PMGC shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 0.0% of PMGC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PMGC's return on equity of -117.82% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
PMGC	N/A	-117.82%	-70.79%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aptevo Therapeutics had 4 more articles in the media than PMGC. MarketBeat recorded 6 mentions for Aptevo Therapeutics and 2 mentions for PMGC. Aptevo Therapeutics' average media sentiment score of 1.28 beat PMGC's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Positive
PMGC	Neutral

PMGC has higher revenue and earnings than Aptevo Therapeutics. Aptevo Therapeutics is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
PMGC	$1.27M	1.14	-$7.75M	-$168.62	N/A

Summary

PMGC beats Aptevo Therapeutics on 7 of the 13 factors compared between the two stocks.

Get PMGC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELAB vs. The Competition

Export

Metric	PMGC	DIVERSIFIED OPS Industry	Multi-Sector Sector	NASDAQ Exchange
Market Cap	$1.45M	$19.22B	$17.62B	$12.24B
Dividend Yield	N/A	4.33%	4.07%	5.82%
P/E Ratio	-0.01	31.98	26.71	24.00
Price / Sales	1.14	5.62	4.78	120.63
Price / Cash	N/A	53.81	51.16	54.51
Price / Book	0.01	4.97	4.38	6.41
Net Income	-$7.75M	$929.92M	$920.57M	$337.14M
7 Day Performance	-12.59%	-1.79%	-1.82%	-0.48%
1 Month Performance	-29.78%	-4.06%	-5.03%	0.48%
1 Year Performance	-99.32%	23.63%	17.66%	28.14%

PMGC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELAB PMGC	0.1282 of 5 stars	$1.25 -5.3%	N/A	-99.2%	$1.45M	$1.27M	N/A	18
ACXP Acurx Pharmaceuticals	2.9445 of 5 stars	$1.54 flat	$31.00 +1,913.0%	-88.2%	$6.62M	N/A	N/A	3
CNSP CNS Pharmaceuticals	2.4036 of 5 stars	$4.53 -2.2%	$20.00 +341.5%	-52.9%	$6.62M	N/A	N/A	5
BMRA Biomerica	1.9468 of 5 stars	$1.97 +2.1%	$9.00 +356.9%	-41.9%	$6.09M	$4.33M	N/A	60	News Coverage Positive News Gap Up
BDRX Biodexa Pharmaceuticals	0.5754 of 5 stars	$3.01 +1.0%	N/A	-94.0%	$6.01M	N/A	N/A	20	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELAB) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PMGC (ELAB) Competitors

ELAB vs. ACXP, CNSP, BMRA, BDRX, and APVO

How does PMGC compare to Acurx Pharmaceuticals?

Summary

How does PMGC compare to CNS Pharmaceuticals?

Summary

How does PMGC compare to Biomerica?

Summary

How does PMGC compare to Biodexa Pharmaceuticals?

Summary

How does PMGC compare to Aptevo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAB vs. The Competition

PMGC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PMGC (ELAB) Competitors

ELAB vs. ACXP, CNSP, BMRA, BDRX, and APVO

How does PMGC compare to Acurx Pharmaceuticals?

Which has preferable valuation & earnings, ELAB or ACXP?

Is ELAB or ACXP more profitable?

Do institutionals and insiders hold more shares of ELAB or ACXP?

Which has more volatility and risk, ELAB or ACXP?

Does the media favor ELAB or ACXP?

Do analysts recommend ELAB or ACXP?

Summary

How does PMGC compare to CNS Pharmaceuticals?

Do analysts recommend ELAB or CNSP?

Is ELAB or CNSP more profitable?

Which has more volatility & risk, ELAB or CNSP?

Does the media favor ELAB or CNSP?

Do insiders and institutionals hold more shares of ELAB or CNSP?

Which has stronger earnings and valuation, ELAB or CNSP?

Summary

How does PMGC compare to Biomerica?

Is BMRA or ELAB more profitable?

Does the media prefer BMRA or ELAB?

Which has more risk and volatility, BMRA or ELAB?

Which has stronger valuation and earnings, BMRA or ELAB?

Do analysts recommend BMRA or ELAB?

Do insiders & institutionals hold more shares of BMRA or ELAB?

Summary

How does PMGC compare to Biodexa Pharmaceuticals?

Do institutionals & insiders have more ownership in BDRX or ELAB?

Which has better valuation and earnings, BDRX or ELAB?

Do analysts rate BDRX or ELAB?

Is BDRX or ELAB more profitable?

Does the media prefer BDRX or ELAB?

Which has more volatility and risk, BDRX or ELAB?

Summary

How does PMGC compare to Aptevo Therapeutics?

Which has more risk & volatility, APVO or ELAB?

Do institutionals & insiders have more ownership in APVO or ELAB?

Is APVO or ELAB more profitable?

Do analysts prefer APVO or ELAB?

Does the media prefer APVO or ELAB?

Which has higher valuation and earnings, APVO or ELAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAB vs. The Competition

PMGC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools